InSilico Medicine Cayman TopCo

As of June 30, 2026, InSilico Medicine Cayman TopCo carries a market capitalization of 22.81B, placing it among publicly traded companies globally. Its enterprise value stands at 18.38B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

InSilico Medicine Cayman TopCo's next confirmed earnings release is scheduled for March 29, 2027.

As of June 30, 2026, InSilico Medicine Cayman TopCo has 575.84M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, InSilico Medicine Cayman TopCo maintains a current ratio of 8.70, meaning it holds 8.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

These figures are as of the close on October 22, 2026. The 50-day moving average sits at 48.85, while the 200-day moving average is 51.72.

As of June 30, 2026, InSilico Medicine Cayman TopCo holds 4.59B in cash and equivalents against 154.13M in total debt, resulting in a net debt position of -2.69B. Total book value stands at 4.29B, with working capital of 4.17B providing operational flexibility.